Tuesday, 22 October 2019

CRO News

  • Biosimilars - the next emerging frontier

    CRO |  Views | By BioSpectrum Bureau  | 0 Comment | 04 Feb, 2013

    The first generation of biological therapeutics were developed in the 1980s. The global biological market represents one of the fastest growing sectors in the healthcare industry. With the ...Read more

  • Is guinea pig theory an overhyped myth?

    CRO |  News | By Rahul Koul Koul | 0 Comment | 24 Aug, 2014

    Ms Radhika (name changed), a patient who has been a part of the clinical trials being done on a drug that could treat her, is happy about the opportunity. Although she doesn't hide the fact...Read more

  • BMS, Pfizer to present clinical trials data on Eliquis

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 22 Aug, 2014

    The new clinical trial data and New Global Health Economics and Outcomes Research (GHEOR) analyses assessing cost effectiveness and real-world use to reinforce the alliance's commitment to ...Read more

  • PPD acquires patented clinical trial design technology

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 08 Sep, 2014

    Pharmaceutical Product Development (PPD), a global CRO firm has announced that it has acquired RCT Logic's exclusive license from Massachusetts General Hospital (MGH) for the portfolio of p...Read more

  • India's contribution a mere 2% in clinical research

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 20 Aug, 2014

    Despite being home to one sixth of the world's population and carrying one fifth of the world's disease burden, yet less than 2 percent of global clinical research takes place in India. Thi...Read more

  • Biotech Cos hesitant to invest in rare disorders R&D

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 21 Aug, 2014

    "We have the talent and the money, however, it is not coordinated into actual deliverables. We have the largest biotech companies here. Many are interested in investing in rare disorders R&...Read more

  • Glenmark develops a novel antibody

    CRO |  News | 0 Comment | 20 Aug, 2014

    The company enters oncology with the discovery and the initiation of IND enabling studies of this innovative bispecific antibody GBR 1302. This is the first bispecific antibody based on Gle...Read more

  • No clinical trials equals no new drugs: ISCR prez

    CRO |  Interviews | By BioSpectrum Bureau  | 0 Comment | 22 Sep, 2014

    Q: What is the current status of clinical research in the country now?Ms Suneela Thatte: Currently clinical research is hit by two primary reasons. Firstly, it is the clinical research revi...Read more

  • Medidata and PPD partner to offer new approach to risk-based monitoring

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 06 Nov, 2014

    Medidata and Pharmaceutical Product Development(PPD) has announced they are expanding their partnership to provide the lifescience industry with a more comprehensive approach to risk-based ...Read more

  • ICON collaborates with Carnegie Mellon University

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 28 Mar, 2015

    ICON has announced that it is sponsoring a series of research projects to find new ways to improve information comprehension and retention by clinical trial participants. The projects are l...Read more

  • ICON completes acquisition of MediMedia Pharma

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 03 Mar, 2015

    ICON has completed the acquisition of MediMedia Pharma Solutions. The acquisition brings ICON new scientific communications capabilities which together with ICON's existing Commercialisatio...Read more

  • CDSCO hands new commandments for pharma cos and CROs

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 17 Sep, 2014

    According to a new order issued by the Central Drugs Standard Control Organization, pharma companies and clinical research organizations (CROs) now need to explain and justify their researc...Read more

  • Mega Merger: IMS Health and Quintiles to combine

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 04 May, 2016

    IMS Health Holdings and Quintiles Transnational Holdings has announced that their respective boards of directors approved a definitive merger agreement, pursuant to which the companies will...Read more

  • AstraZeneca's gout drug completes Phase III trials

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 16 Aug, 2014

    AstraZeneca's drug candidate Lesinurd has successfully finished Phase III trials, as per reports. Three Phase III studies looked at the drug, a selective uric acid (sUA) re-absorption inhib...Read more

  • ICON to acquire MediMedia Pharma Solutions

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 04 Feb, 2015

    ICON has announced that it has agreed to acquire MediMedia Pharma Solutions for a cash consideration of $120 million. The deal is subject to certain customary closing conditions. MediMedia ...Read more

  • Beginning of end to Indian CROs?

    CRO |  Features | By BioSpectrum Bureau  | 0 Comment | 25 Dec, 2014

    Given the countries clinical trial woes already, the fresh new controversy seems to have given yet another major blow to India in the international clinical trials scene. The country is als...Read more

  • Quintiles launches data-driven trial execution powered by Infosario Clinical

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 14 Nov, 2013

    Quintiles has announced the launch of its comprehensive, fully-integrated Data-driven Trial Execution offering, which leverages the concept of risk-based monitoring to improve clinical tria...Read more

  • BioSpectrum Asia's 6th Annual CRO survey findings to be announced this September

    CRO |  News | By BioSpectrum Bureau  | 0 Comment | 11 Aug, 2014

    Bangalore: BioSpectrum Asia will highlight a whole host of issues facing the industry, while tracking the trends of the Asia Pacific region in its annual CRO survey this September. "In an e...Read more